Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -219,879 | -169,166 | -118,556 | -48,501 | -167,575 |
| Depreciation Amortization | 311 | 232 | 153 | 76 | 306 |
| Accounts payable and accrued liabilities | -839 | 40 | 779 | 1,720 | -812 |
| Other Working Capital | 14,084 | 7,940 | 2,395 | -1,793 | -389 |
| Other Operating Activity | 30,573 | 23,313 | 14,465 | 5,343 | 23,167 |
| Operating Cash Flow | $-175,750 | $-137,641 | $-100,764 | $-43,155 | $-145,303 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -49 | -38 | N/A | N/A | N/A |
| Purchase Of Investment | -236,534 | -216,936 | -204,366 | -125,840 | -721,131 |
| Sale Of Investment | 416,572 | 374,572 | 294,572 | 162,645 | 584,817 |
| Investing Cash Flow | $179,989 | $157,598 | $90,206 | $36,805 | $-136,314 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,088 | 373 | 373 | N/A | 270,636 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -4,448 |
| Financing Cash Flow | $1,088 | $373 | $373 | $N/A | $266,188 |
| Beginning Cash Position | 83,005 | 83,005 | 83,005 | 83,005 | 98,434 |
| End Cash Position | 88,332 | 103,335 | 72,820 | 76,655 | 83,005 |
| Net Cash Flow | $5,327 | $20,330 | $-10,185 | $-6,350 | $-15,429 |
| Free Cash Flow | |||||
| Operating Cash Flow | -175,750 | -137,641 | -100,764 | -43,155 | -145,303 |
| Capital Expenditure | -49 | -38 | N/A | N/A | N/A |
| Free Cash Flow | -175,799 | -137,679 | -100,764 | -43,155 | -145,303 |